Full year 2025 ORLADEYO® net revenue of $601.8 million (+38% y-o-y; +43% y-o-y excluding European ORLADEYO revenue following the sale of the ...

Net revenue in Q4 2025 increased by 47% year-over-year to $44.5 million; Net revenue in FY 2025 increased by 25% year-over-year to $146.6 ...

Delivered strong full year 2025 resultsCompleted Initial Public OfferingIntroduced full year 2026 guidanceFourth quarter net sales of $7.8 billion, an increase of 14.8%Fourth quarter net income of ...

C3.ai, Inc. ("C3 AI," "C3," or the "Company") (NYSE: AI), the Enterprise AI application software company, today announced ...

A new study reveals that the next generation of blockchain defenses will not rely on fixed rules alone but on adaptive, learning-based systems capable of evolving alongside intelligent adversaries.

Q4 2025 Earnings Call February 24, 2026 10:00 AM ESTCompany ParticipantsChris BrandonMichael Miles - Chairman of the Board ...

We may earn a commission through links on our site. Why Trust Us? IMAGINE A DAY when all of your biometrics are measured on a ...

Saratoga Investment Corp. has issued a new 7.5% baby bond due 2031, callable in 2028 and after. Click here to find out why SAR is a Hold.

Delivered strong full year 2025 resultsCompleted Initial Public OfferingIntroduced full year 2026 guidanceFourth quarter net sales of $7.8 billion, an increase of 14.8%Fourth quarter net income of $18 ...

Market valued at $1.45B in 2024 grows at 10.4% CAGR driven by biocompatible hemostatic solutions in surgical and trauma ...

ATLANTA, GA / ACCESS Newswire / February 24, 2026 / HAVERTYS (NYSE:HVT) and (NYSE:HVT.A), today reported its operating results for the fourth quarter ended December 31, 2025. Four ...

Full-year 2025 net product revenues of $689 millionSYFOVRE® (pegcetacoplan injection) full year 2025 net product revenue of $587 millionEMPAVELI® (pegcetacoplan) full year 2025 net product revenue of ...